Twist Bioscience Corporation has announced its financial results for the fourth quarter and full year of fiscal 2026, reporting a record revenue of $459.4 million. This figure represents a 22% increase from the $376.6 million reported in fiscal 2025. The company attributes this growth to strong demand for its DNA synthesis and protein solutions, as well as its next-generation sequencing applications.

Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, stated, "Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue growth, expanded gross margin, and positive adjusted EBITDA in the fourth quarter, all while continuing to broaden our capabilities and strengthen our balance sheet." She emphasized the company's commitment to investing in capacity, automation, and new products to better serve its customers.

Twist Bioscience, which operates in the biological products sector (SIC: 2836), has established itself as a key player in the industry. The company is listed on the Nasdaq under the ticker TWST and has been recognized for its innovative approaches to DNA synthesis and related technologies.

The SEC filing, dated November 12, 2026, reveals that Twist's revenue for the fourth quarter of fiscal 2026 reached $126.6 million, an increase of approximately 28% compared to $99.0 million in the same quarter of the previous year. This marks the 15th consecutive quarter of sequential growth for the company.

In addition to its revenue growth, Twist reported a gross margin of 52.4% for fiscal 2026, an improvement of 1.7 margin points from the previous year. The company also provided revenue guidance for fiscal 2027, projecting $550 million to $560 million, which represents a year-over-year growth of 21% at the midpoint.

Twist's performance may influence competitors in the biological products industry, prompting them to enhance their offerings and explore new opportunities for growth. The filing does not specify what actions the company will take next, but the positive financial results indicate a strong foundation for future initiatives.

Overall, Twist Bioscience's financial results for fiscal 2026 reflect a significant achievement, positioning the company for continued success in the rapidly evolving biological products market.